|
US2677682A
(en)
|
1951-08-24 |
1954-05-04 |
American Cyanamid Co |
Sulfonamido pteridines
|
|
ID18983A
(id)
|
1996-12-04 |
1998-05-28 |
Lilly Co Eli |
Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
|
|
SE0001899D0
(sv)
|
2000-05-22 |
2000-05-22 |
Pharmacia & Upjohn Ab |
New compounds
|
|
KR20050044450A
(ko)
|
2001-11-14 |
2005-05-12 |
테바 파마슈티컬 인더스트리즈 리미티드 |
로사르탄 칼륨의 무정형 및 결정형 형태 및 이의 제조 방법
|
|
CN101675928A
(zh)
|
2003-11-14 |
2010-03-24 |
沃泰克斯药物股份有限公司 |
可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑
|
|
BRPI0507278A
(pt)
|
2004-01-30 |
2007-06-26 |
Vertex Pharma |
moduladores dos transportadores do cassete de ligação ao atp
|
|
CA2881078C
(en)
|
2004-06-24 |
2018-10-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
RU2008109031A
(ru)
|
2005-08-11 |
2009-09-20 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Модуляторы муковисцидозного трансмембранного регулятора проводимости
|
|
WO2007053641A2
(en)
|
2005-11-01 |
2007-05-10 |
Mars, Incorporated |
A-type procyanidins and inflammation
|
|
AU2006331565A1
(en)
|
2005-12-27 |
2007-07-05 |
Vertex Pharmaceuticals Incorporated |
Compounds useful in CFTR assays and methods therewith
|
|
US7671221B2
(en)
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
EP2016065B1
(en)
|
2005-12-28 |
2012-09-19 |
Vertex Pharmaceuticals Incorporated |
1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
|
|
LT1993360T
(lt)
|
2005-12-28 |
2017-06-12 |
Vertex Pharmaceuticals Incorporated |
N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
|
|
JP5420395B2
(ja)
|
2006-04-07 |
2014-02-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｐ結合カセット輸送体の調節剤
|
|
ATE534383T1
(de)
|
2006-05-12 |
2011-12-15 |
Vertex Pharma |
Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid
|
|
MX2009004702A
(es)
|
2006-11-03 |
2009-06-19 |
Vertex Pharma |
Derivados de azaindol como moduladores del regulador de conductancia de transmembrana de fibrosis quistica.
|
|
CN101790526A
(zh)
|
2007-06-08 |
2010-07-28 |
雅培制药有限公司 |
用作激酶抑制剂的5-杂芳基取代的吲唑化合物
|
|
RU2010114732A
(ru)
|
2007-09-14 |
2011-10-20 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Твердые формы n-[2,4-бис(1,1-диметилэтил)-5-гидроксифенил]-1,4-дигидро-4-оксохинолин-3-карбоксамида
|
|
HUE049642T2
(hu)
|
2007-12-07 |
2020-09-28 |
Vertex Pharma |
3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
|
|
CA2989620C
(en)
|
2007-12-07 |
2022-05-03 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
|
CA2716109C
(en)
|
2008-02-28 |
2016-07-19 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl derivatives as cftr modulators
|
|
RS56894B1
(sr)
|
2008-08-13 |
2018-04-30 |
Vertex Pharma |
Farmaceutska kompozicija n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
MX2011004375A
(es)
|
2008-10-23 |
2013-03-07 |
Vertex Pharma |
Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
|
|
KR20160013251A
(ko)
|
2008-11-06 |
2016-02-03 |
버텍스 파마슈티칼스 인코포레이티드 |
Ａｔｐ-결합 카세트 수송자의 조절자
|
|
UA104876C2
(uk)
|
2008-11-06 |
2014-03-25 |
Вертекс Фармасьютікалз Інкорпорейтед |
Модулятори atф-зв'язувальних касетних транспортерів
|
|
SI3330255T1
(sl)
|
2009-03-20 |
2021-03-31 |
Vertex Pharmaceuticals Incorporated |
Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
|
|
LT2473170T
(lt)
|
2009-09-04 |
2019-10-10 |
Horizon Orphan Llc |
Aerozolizuoto levofloksacino panaudojimas cistinės fibrozės gydymui
|
|
AU2010310449A1
(en)
|
2009-10-22 |
2012-05-03 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
CN103180298A
(zh)
|
2010-03-19 |
2013-06-26 |
沃泰克斯药物股份有限公司 |
N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式
|
|
EP2563778B1
(en)
|
2010-03-25 |
2016-08-24 |
Vertex Pharmaceuticals Incorporated |
Crystalline form of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide
|
|
TWI549950B
(zh)
|
2010-04-07 |
2016-09-21 |
維泰克斯製藥公司 |
３－（６－（１－（２，２－二氟苯并［ｄ］［１，３］二氧雜環戊烯－５－基）環丙烷甲醯胺基）－３－甲基吡啶－２－基）苯甲酸之固體形式
|
|
ES2900353T3
(es)
|
2010-04-07 |
2022-03-16 |
Vertex Pharma |
Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
|
|
NZ603042A
(en)
|
2010-04-22 |
2015-02-27 |
Vertex Pharma |
Pharmaceutical compositions comprising cftr modulators and administrations thereof
|
|
RU2569678C2
(ru)
|
2010-04-22 |
2015-11-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ получения циклоалкилкарбоксамидо-индольных соединений
|
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
|
JP2013536231A
(ja)
|
2010-08-23 |
2013-09-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
（ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与
|
|
CA2809263A1
(en)
|
2010-08-27 |
2012-03-01 |
Eleni Dokou |
Pharmaceutical composition and administrations thereof
|
|
CN109559148A
(zh)
|
2011-01-04 |
2019-04-02 |
Aq株式会社 |
广告信息提供系统
|
|
ME03652B
(me)
|
2011-05-18 |
2020-07-20 |
Vertex Pharmaceuticals Europe Ltd |
Deuterisani derivati ivakaftora
|
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
|
CN103946221B
(zh)
|
2011-09-16 |
2016-08-03 |
诺华股份有限公司 |
用于治疗囊性纤维化的杂环化合物
|
|
MX2014005304A
(es)
|
2011-10-31 |
2015-03-20 |
Xenon Pharmaceuticals Inc |
Biaril eter sulfonamidas y su uso como agentes terapeuticos.
|
|
CA2852991C
(en)
|
2011-11-08 |
2019-12-31 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
NZ727015A
(en)
|
2012-01-25 |
2017-12-22 |
Vertex Pharma |
Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
EP2819670B1
(en)
|
2012-02-27 |
2026-05-20 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical Composition and Their Administration
|
|
EP2838882A1
(en)
|
2012-04-20 |
2015-02-25 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
GB201207406D0
(en)
|
2012-04-27 |
2012-06-13 |
Glaxo Group Ltd |
Novel compounds
|
|
CA2874621A1
(en)
|
2012-05-22 |
2013-11-28 |
Genentech, Inc. |
N-substituted benzamides and their use in the treatment of pain
|
|
AU2013270681A1
(en)
|
2012-06-08 |
2014-12-18 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of CFTR -mediated disorders
|
|
AU2013290444B2
(en)
|
2012-07-16 |
2018-04-26 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
|
KR102396897B1
(ko)
|
2012-11-02 |
2022-05-13 |
버텍스 파마슈티칼스 인코포레이티드 |
Ｃｆｔｒ 매개된 질환의 치료를 위한 약제학적 조성물
|
|
WO2014078842A1
(en)
|
2012-11-19 |
2014-05-22 |
Concert Pharmaceuticals, Inc. |
Deuterated cftr potentiators
|
|
WO2015051043A1
(en)
|
2013-10-01 |
2015-04-09 |
Amgen Inc. |
Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
|
|
CA2930199C
(en)
|
2013-11-12 |
2022-10-25 |
Vertex Pharmaceuticals Incorporated |
Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
|
|
PL3925607T5
(pl)
|
2014-04-15 |
2026-06-01 |
Vertex Pharmaceuticals Incorporated |
Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
|
|
TW202140422A
(zh)
|
2014-10-06 |
2021-11-01 |
美商維泰克斯製藥公司 |
囊腫纖維化症跨膜傳導調節蛋白之調節劑
|
|
CA2963945C
(en)
|
2014-10-07 |
2023-01-10 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
|
HUE055423T2
(hu)
|
2014-11-18 |
2021-11-29 |
Vertex Pharma |
Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
|
|
WO2016121399A1
(ja)
|
2015-01-29 |
2016-08-04 |
京セラ株式会社 |
測定装置およびセンサシステム
|
|
US10196384B2
(en)
|
2015-03-31 |
2019-02-05 |
Vertex Pharmaceuticals (Europe) Limited |
Deuterated CFTR modulators
|
|
US9840513B2
(en)
|
2015-07-16 |
2017-12-12 |
Abbvie S.Á.R.L. |
Substituted tricyclics and method of use
|
|
HK1258472A1
(zh)
|
2015-09-21 |
2019-11-15 |
Vertex Pharmaceuticals (Europe) Limited |
氘代cftr增效剂的施用
|
|
HK1258473A1
(zh)
|
2015-09-25 |
2019-11-15 |
Vertex Pharmaceuticals (Europe) Limited |
氘代cftr增效剂
|
|
US10766858B2
(en)
|
2016-03-30 |
2020-09-08 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
ES2946970T3
(es)
|
2016-03-31 |
2023-07-28 |
Vertex Pharma |
Regulador de conductancia transmembrana de moduladores de fibrosis quística
|
|
WO2017177124A1
(en)
|
2016-04-07 |
2017-10-12 |
Proteostasis Therapeutics, Inc. |
Silicone atoms containing ivacaftor analogues
|
|
AU2017256172A1
(en)
|
2016-04-26 |
2018-09-06 |
AbbVie S.à.r.l. |
Modulators of cystic fibrosis transmembrane conductance regulator protein
|
|
US10138227B2
(en)
|
2016-06-03 |
2018-11-27 |
Abbvie S.Á.R.L. |
Heteroaryl substituted pyridines and methods of use
|
|
ES2954658T3
(es)
|
2016-06-21 |
2023-11-23 |
Proteostasis Therapeutics Inc |
Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR
|
|
US20180012171A1
(en)
|
2016-07-05 |
2018-01-11 |
Elie Massabki |
On-demand resource allocation
|
|
TW201811766A
(zh)
|
2016-08-29 |
2018-04-01 |
瑞士商諾華公司 |
N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
|
|
GEP20217329B
(en)
|
2016-09-30 |
2021-12-10 |
Vertex Pharma |
Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
|
|
US9981910B2
(en)
|
2016-10-07 |
2018-05-29 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
US10399940B2
(en)
|
2016-10-07 |
2019-09-03 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
EP3532461A1
(en)
|
2016-10-26 |
2019-09-04 |
Proteostasis Therapeutics, Inc. |
N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
|
|
US20190248779A1
(en)
|
2016-10-26 |
2019-08-15 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
CA3041676A1
(en)
|
2016-10-26 |
2018-05-03 |
Daniel Parks |
Pyridazine derivatives, compositions and methods for modulating cftr
|
|
AU2017352206B2
(en)
|
2016-10-27 |
2022-03-03 |
Vertex Pharmaceuticals (Europe) Limited |
Methods of treatment with deuterated CFTR potentiators
|
|
SG10202106949XA
(en)
|
2016-11-18 |
2021-07-29 |
Cystic Fibrosis Found |
Pyrrolopyrimidines as cftr potentiators
|
|
EA202192783A1
(ru)
|
2016-12-09 |
2022-02-24 |
Вертекс Фармасьютикалз Инкорпорейтед |
Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
|
|
CN110300589B
(zh)
|
2016-12-16 |
2023-03-10 |
囊性纤维化基金会 |
作为cftr增效剂的双环异杂芳基衍生物
|
|
WO2018116185A1
(en)
|
2016-12-20 |
2018-06-28 |
AbbVie S.à.r.l. |
Deuterated cftr modulators and methods of use
|
|
CN110177788B
(zh)
|
2017-01-07 |
2023-03-24 |
重庆复创医药研究有限公司 |
作为bcl-2选择性凋亡诱导剂的化合物
|
|
TW201831471A
(zh)
|
2017-02-24 |
2018-09-01 |
盧森堡商艾伯維公司 |
囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
|
|
US20180280349A1
(en)
|
2017-03-28 |
2018-10-04 |
Vertex Pharmaceuticals Incorporated |
Methods of treating cystic fibrosis in patients with residual function mutations
|
|
MX2019010302A
(es)
|
2017-03-30 |
2019-11-21 |
Hoffmann La Roche |
Isoquinolinas como inhibidores de hpk1.
|
|
CA3061476A1
(en)
|
2017-04-28 |
2018-11-01 |
Proteostasis Therapeutics, Inc. |
4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity
|
|
MA54105A
(fr)
|
2017-06-08 |
2021-09-15 |
Vertex Pharma |
Méthodes de traitement de la fibrose kystique
|
|
CA3068609A1
(en)
|
2017-07-01 |
2019-01-10 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of cystic fibrosis
|
|
AU2018300150A1
(en)
|
2017-07-11 |
2020-01-30 |
Vertex Pharmaceuticals Incorporated |
Carboxamides as modulators of sodium channels
|
|
CA3069225A1
(en)
|
2017-07-17 |
2019-01-24 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
|
IL272032B2
(en)
|
2017-07-17 |
2026-04-01 |
Vertex Pharma |
Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and
|
|
MA49752A
(fr)
|
2017-08-02 |
2021-04-21 |
Vertex Pharma |
Procédés de préparation de composés de pyrrolidine
|
|
US10988454B2
(en)
|
2017-09-14 |
2021-04-27 |
Abbvie Overseas S.À.R.L. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
US20210369749A1
(en)
|
2017-10-06 |
2021-12-02 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
CA3078893A1
(en)
|
2017-10-19 |
2019-04-25 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms and compositions of cftr modulators
|
|
WO2019109021A1
(en)
|
2017-12-01 |
2019-06-06 |
Vertex Pharmaceuticals Incorporated |
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2019113089A1
(en)
|
2017-12-04 |
2019-06-13 |
Vertex Pharmaceuticals Incorporated |
Compositions for treating cystic fibrosis
|
|
KR102716244B1
(ko)
|
2017-12-08 |
2024-10-14 |
버텍스 파마슈티칼스 인코포레이티드 |
낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
|
|
TWI810243B
(zh)
|
2018-02-05 |
2023-08-01 |
美商維泰克斯製藥公司 |
用於治療囊腫纖化症之醫藥組合物
|
|
RS64018B1
(sr)
|
2018-02-15 |
2023-03-31 |
Vertex Pharma |
Makrocikli kao modulatori transmembranskog regulatora provodnosti cistične fibroze, njihove farmaceutske kompozicije, njihova upotreba u lečenju cistične fibroze i proces njihove izrade
|
|
WO2019191620A1
(en)
|
2018-03-30 |
2019-10-03 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of modulators of cftr
|
|
WO2019195739A1
(en)
|
2018-04-05 |
2019-10-10 |
Alexander Russell Abela |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2019200246A1
(en)
*
|
2018-04-13 |
2019-10-17 |
Alexander Russell Abela |
Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
|
|
MA54227B1
(fr)
|
2018-11-14 |
2023-03-31 |
Vertex Pharma |
Méthodes de traitement de la fibrose kystique
|
|
EP3898621A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Macrocyclic compounds and their use in the treatment of disease
|
|
JP2022519301A
(ja)
|
2019-02-06 |
2022-03-22 |
ノバルティス アーゲー |
Ｎ－（ピリジン－２－イル）ピリジン－スルホンアミド誘導体及び疾患の処置におけるそれらの使用
|
|
WO2020191227A1
(en)
|
2019-03-20 |
2020-09-24 |
Cornell University |
Methods for controlling prostaglandin-mediated biological processes
|
|
TWI848092B
(zh)
|
2019-04-03 |
2024-07-11 |
美商維泰克斯製藥公司 |
囊腫纖維化跨膜傳導調節蛋白調節劑
|
|
WO2020214921A1
(en)
|
2019-04-17 |
2020-10-22 |
Vertex Pharmaceuticals Incorporated |
Solid forms of modulators of cftr
|
|
WO2020242935A1
(en)
|
2019-05-29 |
2020-12-03 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
|
TWI867024B
(zh)
|
2019-08-14 |
2024-12-21 |
美商維泰克斯製藥公司 |
囊腫纖維化跨膜傳導調節蛋白之調節劑
|
|
TWI899097B
(zh)
|
2019-08-14 |
2025-10-01 |
美商維泰克斯製藥公司 |
製備cftr調節劑之方法
|
|
US11873300B2
(en)
|
2019-08-14 |
2024-01-16 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of CFTR modulators
|
|
WO2021030556A1
(en)
|
2019-08-14 |
2021-02-18 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
MX2022005810A
(es)
|
2019-11-12 |
2022-06-08 |
Genzyme Corp |
Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de regulador de la conductancia transmembrana de la fibrosis quistica (cftr) deficiente.
|
|
CA3158057A1
(en)
|
2019-11-12 |
2021-05-20 |
Genzyme Corporation |
5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity
|
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
|
WO2022036060A1
(en)
|
2020-08-13 |
2022-02-17 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of cftr modulators
|
|
WO2022076626A1
(en)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2022076620A1
(en)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
BR112023006470A2
(pt)
|
2020-10-07 |
2023-09-26 |
Vertex Pharma |
Moduladores de regulador de condutância transmembrana de fibrose cística
|
|
US20230382924A1
(en)
|
2020-10-07 |
2023-11-30 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
MX2023004072A
(es)
|
2020-10-07 |
2023-07-05 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.
|
|
TW202233635A
(zh)
|
2020-10-07 |
2022-09-01 |
美商維泰克斯製藥公司 |
囊腫纖維化跨膜傳導調節蛋白之調節劑
|
|
MX2023006770A
(es)
|
2020-12-10 |
2023-08-14 |
Vertex Pharma |
Metodos de tratamiento para fibrosis quistica.
|